Zsolt Talloczy

Zsolt Talloczy, PhD, is a prominent pharmaceutical professional currently serving as the Director of Clinical Development at Novartis, a role he has held since March 2017. He has extensive experience in clinical research, particularly in the areas of dermatology and rheumatology, where he has been instrumental in the global development of treatments such as Cosentyx (secukinumab) for conditions like ankylosing spondylitis and psoriasis.14

Professional Background

• Current Position: Director of Clinical Development at Novartis (March 2017 - Present)
• Previous Roles:
  • Associate Director, Clinical Sciences for COSENTYX Global Clinical Development (May 2013 - Present)
  • Expert CM and Senior CM at Novartis, contributing to the development of Gilenya for multiple sclerosis from Phase III to post-approval phases.1
  • Research Scientist at Columbia University Medical Center (2003 - 2008), focusing on cellular and molecular biology related to neurodegeneration.1

Key Contributions

• Clinical Trials: Zsolt has led multiple clinical trials (Phase II and III) and was key in the scientific study protocol development for various indications. His leadership has facilitated the approval processes for significant therapeutic products.12
• Publications and Research: He has authored numerous publications and contributed to significant studies regarding drug efficacy and safety, including recent work on inclisiran for lowering LDL cholesterol in patients with familial hypercholesterolemia.23

Education

Zsolt Talloczy earned his PhD from Columbia University, where he conducted research that contributed to advancements in understanding neurodegenerative diseases.14

Contact Information

Zsolt can be reached through his professional email at Novartis or via his LinkedIn profile under the username zsolttalloczy.15